Skip to main content

Table 1 Population characteristics of US adults ≥20 years of age with and without CKD stage 1–4* based on NHANES 2001–2010 survey participants

From: Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010

Characteristic

With CKD

Without CKD

P †

 

(n=1,428)

(n=8,487)

 

Age at screening (years)

64.2 (0.7)

44.5 (0.3)

<0.001

Male (%)

41.7 (1.5)

49.5 (0.5)

<0.001

Race/ethnicity (%)

  

0.001

  Non-Hispanic white

75.4 (2.1)

71.2 (1.4)

 

  Non-Hispanic black

11.6 (1.1)

10.7 (0.8)

 

  Mexican American

5.7 (0.9)

8.0 (0.7)

 

  Other

7.3 (1.4)

10.1 (0.8)

 

eGFR (mL/min/1.73 m2)

68.4 (1.0)

97.9 (0.4)

<0.001

Body mass index (kg/m2)

29.7 (0.3)

28.2 (0.1)

<0.001

 

(n=1,372)

(n=8,398)

 

Blood pressure (mmHg)

   

  Systolic

133.2 (0.8)

119.4 (0.2)

<0.001

  Diastolic

67.5 (0.6)

70.2 (0.2)

<0.001

Lipids (mg/dL)

   

  Total cholesterol

194.3 (1.4)

196.4 (0.6)

0.1

  LDL-C

111.4 (1.1)

117.6 (0.5)

<0.001

  HDL-C

54.4(0.5)

54.0 (0.2)

0.6

  Triglycerides

142.6 (2.4)

124.2 (1.0)

<0.001

Antidiabetic medication use (%)‡§

21.0 (1.4)

4.8 (0.2)

<0.001

  1. Values are weighted estimates presented as percent (standard error) or mean (standard error). Estimates were standardized to the July 2008 US census population ≥20 years of age. Conversion factors for units: eGFR in mL/min/1.73 m2 to mL/s/1.73 m2, ×0.01667; total cholesterol, LDL-C and HDL-C in mg/dL to mmol/L, ×0.02586; triglycerides in mg/dL to mmol/L, ×0.01129; glucose in mg/dL to mmol/L, ×0.05551.
  2. *CKD Stage 1–4 was identified by the presence of kidney damage (based on albuminuria) and level of decline in kidney function (based on eGFR), and staged using modified National Kidney Foundation criteria (see Methods).
  3. †P values are for with versus without CKD; P value for race/ethnicity compares the distribution of race/ethnicity categories. Rao-Scott chi-square P values for categorical variables were obtained using the SAS procedure SURVEYFREQ; between-cohort P values for continuous variables were obtained using the SAS procedure SURVEYREG (see Methods).
  4. ‡All drug utilization was self-reported.
  5. §Any antidiabetic agents including insulin and oral medications for diabetes.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us